DOCSLIB.ORG

JSH 2004) 4Ii

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

3 Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2004) 4ii Guidelines Subcommittee Chair Takao SARUTA Keio University Members Tanenao ETO Miyazaki University Toshiro FUJITA The University of Tokyo Yutaka IMAI Tohoku University Tsutomu IMAIZUMI Kurume University Sadayoshi ITO Tohoku University Kenjiro KIKUCHI Asahikawa Medical College Masayasu MATSUMOTO Hiroshima University Hiroaki MATSUOKA Dokkyo Medical University Toshio OGIHARA Osaka University Kazuyuki SHIMADA Jichi Medical University School of Medicine Kazuaki SHIMAMOTO Sapporo Medical University Hiromichi SUZUKI Saitama Medical University Shuichi TAKISHITA University of the Ryukyus Hisaichiro TSUKIYAMA International University of Health and Welfare Makoto UCHIYAMA Niigata University Hirotsugu UESHIMA Shiga University of Medical Science Reviewers Keishi ABE Tohoku University Kikuo ARAKAWA Fukuoka University Masatoshi FUJISHIMA Kyushu University Koshiro FUKIYAMA University of the Ryukyus Toshihiko HASEGAWA National Institute of Public Health Kunio HIWADA Ehime University Osamu IIMURA Sapporo Medical University Masao ISHII Yokohama City University Yoshihiro KANEKO Yokohama City University Teruo OMAE National Cardiovascular Center Akira TAKESHITA Kyushu University Yoshio YAZAKI National Hospital Organization Kaoru YOSHINAGA Tohoku University Secretary Ikuo SAITO Keio University Support staff Isao ABE Kitakyushu Wakamatsu Hospital Katsuyuki ANDO The University of Tokyo Naoyuki HASEBE Asahikawa Medical College Hiroshi HIROSE Keio University Toshihiro KITA Miyazaki University Tatsuo SHIMOSAWA The University of Tokyo (in alphabetical order) iii5 Volume 29, Supplement, August, 2006 CONTENTS 1. Epidemiology of Hypertension S1 1) Changes in the Average Blood Pressure of the Japanese S1 2) Hypertension and Occurrence of Cardiovascular Diseases and Its Prognosis S1 a. High Incidence of Stroke Due to Hypertension S1 b. Development of Heart Diseases Due to Hypertension S1 c. Prognosis of Stroke and Heart Disease S2 3) Characteristics of Hypertension in the Japanese S2 a. High Salt Intake S2 b. Obesity S5 c. Untreated Hypertensive Patients and Poor Management of Hypertension S5 4) Preventive Measures against Hypertension from the Viewpoint of Public Health S5 Summary S6 2. Measurement and Clinical Evaluation of the Blood Pressure S7 1) Measurement of Blood Pressure S7 a. Measurement of Blood Pressure at the Clinical Setting S7 b. Home Blood Pressure Measurement S7 c. Ambulatory Blood Pressure Monitoring S8 d. Information Obtained by the Home Blood Pressure Measurement and Ambulatory Blood Pressure Monitoring S9 2) Classification of Blood Pressure Values and Evaluation of Risk Factors S10 a. Classification of Blood Pressure Values S10 b. Risk Factors for Cardiovascular Diseases S11 c. Stratification of Risk for Evaluation of the Prognosis S11 d. Types of Hypertension S12 3) Examination and Diagnosis S12 a. History S12 b. Examination (Physical Findings) S13 c. Laboratory Examinations S13 d. Diagnosis of Hypertensive Target Organ Damage S13 4) Planning for the Control of Hypertension at the Initial Examination S14 Summary S14 3. Basic Principles of Treatment S15 1) Objectives of Treatment S15 2) Patients to Be Treated and Target Levels of Blood Pressure S16 a. Patients to Be Treated S16 b. Target Levels of Blood Pressure S16 3) Selection of Treatments S17 a. Lifestyle Modifications S17 b. Time to Start Antihypertensive Drug Treatment S17 c. Antihypertensive Drug Treatment S17 4) Other Points of Attention S18 a. Initial Treatment S18 b. Long-Term Treatment (Continuous Treatment) S18 c. Attention to the Quality of Life S18 Summary S19 4. Lifestyle Modifications S21 1) Restriction of the Salt Intake (Reduced-Salt Diet) S21 2) Increases in the Intake of Vegetables and Fruits and Restriction of the Intake of Cholesterol and Saturated Fatty Acids S22 3) Maintaining a Proper Body Weight (Weight Control) S24 4) Exercise Therapy S24 5) Restriction of Alcohol Intake (Moderation in Drinking) S24 6) No Smoking S24 6iv 7) Other Cautions about Daily Living S25 8) Comprehensive Lifestyle Modifications S25 Summary S25 5. Treatment with Antihypertensive Drugs S27 1) Basic Principles for Choice of Antihypertensive Drugs S27 a. Choice of Antihypertensive Drugs S27 b. Use of Antihypertensive Drugs S27 c. Drug Interactions S28 d. Dose Reduction and Withdrawal of Antihypertensive Drugs S28 2) Characteristics and Major Adverse Effects of Various Antihypertensive Drugs S28 a. Ca Antagonists S28 b. Angiotensin II Receptor Blockers S29 c. Angiotensin-Converting Enzyme Inhibitors S29 d. Diuretics S30 e. β-Blockers (Including αβ-Blockers) S31 f. α-Blockers S31 g. Other Sympatholytic Agents—Centrally and Peripherally Acting Drugs S31 h. Classic Vasodilators S32 3) Designated Health-Promoting Foods S32 Summary S32 6. Hypertension Associated with Organ Damage S33 1) Cerebrovascular Disease S33 a. Acute Phase S33 b. Chronic Phase S34 c. Asymptomatic Phase S35 2) Heart Diseases S36 a. Ischemic Heart Disease S36 b. Treatment for Heart Failure Using Antihypertensive Drugs S37 c. Cardiac Hypertrophy S38 3) Kidney Diseases S38 a. Renal Function and Blood Pressure S38 b. Chronic Kidney Diseases and Cardiovascular Diseases S39 c. Lifestyle Modifications S39 d. Antihypertensive Drug Treatment S39 e. Patients Undergoing Dialysis S41 4) Vascular Diseases S42 a. Aortic Aneurysm S42 b. Atherosclerotic Peripheral Arterial Obstruction S42 Summary S42 7. Hypertension Complicated by Other Diseases S45 1) Diabetes Mellitus S45 2) Hyperlipidemia S47 3) Obesity S47 4) Metabolic Syndrome S47 5) Bronchial Asthma and Chronic Obstructive Pulmonary Disease S48 6) Gout and Hyperuricemia S48 7) Liver Diseases S49 Summary S49 8. Hypertension in the Elderly S51 1) Characteristics of Hypertension in the Elderly S51 2) Criteria and Diagnosis of Hypertension in the Elderly S51 3) Treatment S52 a. Effects of Antihypertensive Therapy in the Elderly S52 b. Indications for Antihypertensive Therapy and Target Levels of Blood Pressure S54 c. Lifestyle Modifications S55 d. Choice of Antihypertensive Drugs S56 Summary S58 7v 9. Hypertension under Special Conditions S59 1) Refractory Hypertension S59 a. Definition and Frequency S59 b. Causes and Preventive Measures S59 2) Hypertensive Emergency and Urgency S60 a. Definitions and Classification S60 b. Principles of Treatment S61 c. Hypertensive Encephalopathy S61 d. Cerebrovascular Diseases S62 e. Acute Left Ventricular Failure and Pulmonary Edema S62 f. Severe Hypertension Complicating Acute Coronary Syndrome, Acute Myocardial Infarction, or Unstable Angina S62 g. Pheochromocytoma Crisis S62 h. Accelerated/Malignant Hypertension S63 i. Cases with Increases in Blood Pressure Other than Hypertensive Emergency S64 3) Blood Pressure Management at Pre- and Post-Surgery S64 4) Hypertension in Women S65 a. Hypertension in Pregnancy S65 b. Hypertension Related to the Use of Oral Contraceptives and Estrogen Replacement Therapy S67 c. Hypertension in Postmenopausal Women S67 Summary S67 10. Hypertension in Children S69 1) Characteristics of Hypertension in Children and High School Students S69 2) Measurement of Blood Pressure and Diagnostic Criteria of Hypertension for Children S69 3) Problems with Essential Hypertension in Children and High School Students S69 4) Lifestyle Modifications in Childhood (Primary Prevention of Hypertension) S69 a. Dietary Therapy S71 b. Exercise Therapy S71 5) Management of Hypertension S71 6) Antihypertensive Drug Treatment S71 Summary S72 11. Secondary Hypertension S73 1) Prevalence of Secondary Hypertension S73 2) Renal Parenchymal Hypertension S73 a. Diabetic Nephropathy S73 b. Chronic Glomerulonephritis S74 c. Polycystic Kidney Disease S74 3) Renovascular Hypertension S74 a. Diagnostic Clues S76 b. Examinations for the Diagnosis S76 c. Treatments S76 4) Endocrine Hypertension S77 a. Primary Aldosteronism and Similar Diseases S77 b. Cushing’s Syndrome S78 c. Pheochromocytoma S79 d. Thyroid Diseases S79 e. Hyperparathyroidism (Primary) S80 f. Acromegaly S80 5) Vascular Hypertension S80 a. Aortitis Syndrome S80 b. Other Angitis S80 c. Coarctation of Aorta S80 d. Vascular Hypertension Accompanied by an Increase in the Cardiac Output S81 6) Hypertension Due to Diseases of the Brain or the Central Nervous System S81 7) Drug-Induced Hypertension S81 a. Non-Steroidal Anti-Inflammatory Drugs S81 b. Licorice (Glycyrrhizin) S81 c. Glucocorticoids S82 8vi d. Cyclosporine S82 e. Erythropoietin S82 f. Drugs with Sympathomimetic Actions S82 g. Others S83 Summary S83 References S85 Main Antihypertensive Drugs S103 Hypertension Research (ISSN 0916-9636) has been published monthly since 2003 by the Japanese Society of Hypertension. The Journal succeeds the Japanese Journal of Hypertension which had been published since 1978 in Japanese edition and has been renewed in 1992, from Volume 15. Correspondence Kazuyuki Shimada, M.D. (Editor-in-Chief Hypertension Research) Division of Cardiovascular Medicine, Jichi Medical University School of Medicine 3311–1 Yakushiji, Shimotsuke 329–0498, Japan Tel: +81 (0)285-58-7538 Fax: +81 (0)285-44-4311 E-mail: [email protected] Subscription Rates Annual subscription is accepted at any time. These list prices are effective since 2000. In Japan: For individuals subscription rate is ¥15,000/year. For institution: ¥20,000/year. All orders must be sent to the Japanese Society of Hypertension. Members of the Japanese Society of Hypertension are eligible for a reduced rate. Contact the Japanese Society of Hypertension [Rm4F,
Recommended publications
  • Specifications of Approved Drug Compound Library

    Specifications of Approved Drug Compound Library

    Annexure-I : Specifications of Approved drug compound library The compounds should be structurally diverse, medicinally active, and cell permeable Compounds should have rich documentation with structure, Target, Activity and IC50 should be known Compounds which are supplied should have been validated by NMR and HPLC to ensure high purity Each compound should be supplied as 10mM solution in DMSO and at least 100µl of each compound should be supplied. Compounds should be supplied in screw capped vial arranged as 96 well plate format.
  • Identification of Compounds That Rescue Otic and Myelination

    Identification of Compounds That Rescue Otic and Myelination

    RESEARCH ARTICLE Identification of compounds that rescue otic and myelination defects in the zebrafish adgrg6 (gpr126) mutant Elvira Diamantopoulou1†, Sarah Baxendale1†, Antonio de la Vega de Leo´ n2, Anzar Asad1, Celia J Holdsworth1, Leila Abbas1, Valerie J Gillet2, Giselle R Wiggin3, Tanya T Whitfield1* 1Bateson Centre and Department of Biomedical Science, University of Sheffield, Sheffield, United Kingdom; 2Information School, University of Sheffield, Sheffield, United Kingdom; 3Sosei Heptares, Cambridge, United Kingdom Abstract Adgrg6 (Gpr126) is an adhesion class G protein-coupled receptor with a conserved role in myelination of the peripheral nervous system. In the zebrafish, mutation of adgrg6 also results in defects in the inner ear: otic tissue fails to down-regulate versican gene expression and morphogenesis is disrupted. We have designed a whole-animal screen that tests for rescue of both up- and down-regulated gene expression in mutant embryos, together with analysis of weak and strong alleles. From a screen of 3120 structurally diverse compounds, we have identified 68 that reduce versican b expression in the adgrg6 mutant ear, 41 of which also restore myelin basic protein gene expression in Schwann cells of mutant embryos. Nineteen compounds unable to rescue a strong adgrg6 allele provide candidates for molecules that may interact directly with the Adgrg6 receptor. Our pipeline provides a powerful approach for identifying compounds that modulate GPCR activity, with potential impact for future drug design. DOI: https://doi.org/10.7554/eLife.44889.001 *For correspondence: [email protected] †These authors contributed Introduction equally to this work Adgrg6 (Gpr126) is an adhesion (B2) class G protein-coupled receptor (aGPCR) with conserved roles in myelination of the vertebrate peripheral nervous system (PNS) (reviewed in Langenhan et al., Competing interest: See 2016; Patra et al., 2014).
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1

    Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1

    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
  • A Comparative Effectiveness Meta-Analysis of Drugs for the Prophylaxis of Migraine Headache

    A Comparative Effectiveness Meta-Analysis of Drugs for the Prophylaxis of Migraine Headache

    University of South Florida Masthead Logo Scholar Commons School of Information Faculty Publications School of Information 7-2015 A Comparative Effectiveness Meta-Analysis of Drugs for the Prophylaxis of Migraine Headache Authors: Jeffrey L. Jackson, Elizabeth Cogbill, Rafael Santana-Davila, Christina Eldredge, William Collier, Andrew Gradall, Neha Sehgal, and Jessica Kuester OBJECTIVE: To compare the effectiveness and side effects of migraine prophylactic medications. DESIGN: We performed a network meta-analysis. Data were extracted independently in duplicate and quality was assessed using both the JADAD and Cochrane Risk of Bias instruments. Data were pooled and network meta-analysis performed using random effects models. DATA SOURCES: PUBMED, EMBASE, Cochrane Trial Registry, bibliography of retrieved articles through 18 May 2014. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: We included randomized controlled trials of adults with migraine headaches of at least 4 weeks in duration. RESULTS: Placebo controlled trials included alpha blockers (n = 9), angiotensin converting enzyme inhibitors (n = 3), angiotensin receptor blockers (n = 3), anticonvulsants (n = 32), beta-blockers (n = 39), calcium channel blockers (n = 12), flunarizine (n = 7), serotonin reuptake inhibitors (n = 6), serotonin norepinephrine reuptake inhibitors (n = 1) serotonin agonists (n = 9) and tricyclic antidepressants (n = 11). In addition there were 53 trials comparing different drugs. Drugs with at least 3 trials that were more effective than placebo for episodic migraines
  • Intérêts Et Limites De La Bile Et De L'humeur Vitrée Comme Matrices Alternatives En Toxicologie Médicolégale

    Intérêts Et Limites De La Bile Et De L'humeur Vitrée Comme Matrices Alternatives En Toxicologie Médicolégale

    Intérêts et limites de la bile et de l’humeur vitrée comme matrices alternatives en toxicologie médicolégale. Fabien Bévalot To cite this version: Fabien Bévalot. Intérêts et limites de la bile et de l’humeur vitrée comme matrices alternatives en toxicologie médicolégale.. Toxicologie. Université Claude Bernard - Lyon I, 2014. Français. NNT : 2014LYO10362. tel-01167119 HAL Id: tel-01167119 https://tel.archives-ouvertes.fr/tel-01167119 Submitted on 23 Jun 2015 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Année 2014 THESE DE L'UNIVERSITE DE LYON Délivrée par L'UNIVERSITE CLAUDE BERNARD LYON 1 ECOLE DOCTORALE INTERDISCIPLINAIRE SCIENCES-SANTE (E.D.I.S.S.) DIPLOME DE DOCTORAT (arrêté du 7 aout 2006) Soutenue publiquement le 17 décembre 2014 Par M BÉVALOT Fabien INTERETS ET LIMITES DE LA BILE ET DE L'HUMEUR VITREE COMME MATRICES ALTERNATIVES EN TOXICOLOGIE MEDICOLEGALE Directeurs de Thèse : Pr. GUITTON Jérôme Pr. FANTON Laurent JURY: Pr. Michel Tod (Président du Jury) Pr. Marc Augsburger (Rapporteur) Dr. Pascal Kintz (Rapporteur) Dr. Hélène Eysseric (Examinatrice) Pr. Laurent Fanton (Directeur de Thèse) Pr. Jérôme Guitton (Directeur de Thèse) UNIVERSITE CLAUDE BERNARD - LYON 1 Président de l’Université M.
  • A2) United States Patent (0) Patent No.: US 9,078,919 B2 Olsonet Al

    A2) United States Patent (0) Patent No.: US 9,078,919 B2 Olsonet Al

    US009078919B2 a2) United States Patent (0) Patent No.: US 9,078,919 B2 Olsonet al. (45) Date of Patent: *Jul. 14, 2015 (54) MICRO-RNAS OF THE MIR-15 FAMILY 2005/0182011 Al 8/2005 Olson etal. MODULATE CARDIOMYOCYTE SURVIVAL 2006/0058266 Al 3/2006 Manoharan etal. AND CARDIAC REPAIR 2006/0105360 Al 5/2006 Croce etal. 2006/0165659 Al 7/2006 Croceet al. 2006/0185027 Al 8/2006 Bartelet al. (71) Applicant: The Board of Regents, The University 2006/0189557 Al 8/2006 Slack et al. of Texas System, Austin, TX (US) 2006/0247193 Al 11/2006 Taira et al. 2006/0252722 Al 11/2006 Lollo et al. (72) Inventors: Eric N. Olson, Dallas, TX (US); Eva 2007/0026403 Al 2/2007 Hatzigeorgiouetal. 2007/0054287 Al 3/2007 Bloch van Rooij, Utrecht (NL) 2007/0213292 Al 9/2007 Stoffel et al. 2007/0259827 Al 11/2007 Aronin et al. (73) Assignee: The Board of Regents, the University 2007/0287179 Al 12/2007 Tuschletal. of Texas System, Austin, TX (US) 2007/0292878 Al 12/2007 Raymond. 2008/0050744 Al 2/2008 Brownetal. (*) Notice: Subject to any disclaimer, the term of this 2008/0176766 Al 7/2008 Brownetal. 2008/0220423 Al 9/2008 Molleret al. patent is extended or adjusted under 35 2009/0053718 Al 2/2009 Naguibnevaetal. U.S.C. 154(b) by 0 days. 2009/0092980 Al 4/2009 Arenzet al. 2009/0131356 Al 5/2009 Baderet al. This patent is subject to a terminal dis- 2009/0176723 Al 7/2009 Brownetal. claimer. 2009/0214477 Al 8/2009 Betzet al.
  • Hormonal and Metabolic Response to Operative Stress in the Neonate

    Hormonal and Metabolic Response to Operative Stress in the Neonate

    Hormonal and Metabolic Response to Operative Stress in the Neonate DAVID J. SCHMELING, M.D. AND ARNOLD G. CORAN, M.D. From the Section of Pediatric Surgery, Mott Children’s Hospital and University of Michigan Medical School, Ann Arbor, Michigan ABSTRACT. It is evident from this review that newborns, primarily catabolic in nature because the combined hormonal even those born prematurely, are capable of mounting an changes include an increased release of catabolic hormones endocrine and metabolic response to operative stress. Unfor- such as catecholamines, glucagon, and corticosteroids coupled tunately, many of the areas for which a relatively well-charac- with a suppression of and peripheral resistance to the effects terized response exists in adults are poorly documented in of the primary anabolic hormone, insulin. (Journal of Paren- neonates. As is the case in adults, the response seems to be teral and Enteral Nutrition 15:215-238, 1991) It is apparent that adult patients demonstrate a cata- are subjected to greatly increased rates of complications bolic response to the stresses induced by operative or such as cardiac or pulmonary insufficiency, myocardial accidental trauma. It seems that the degree of this cata- infarction, impaired hepatic and/or renal function, gas- bolic response may be quantitatively related to the extent tric stress ulcers, and sepsis. Furthermore, evidence ex- of the trauma or the magnitude of associated complica- ists to suggest that this response may be life threatening tions such as infection. The host response to infection, if the induced catabolic activity remains excessive or traumatic injury, or major operative stress is character- unchecked for a prolonged period.
  • WO 2013/061161 A2 2 May 2013 (02.05.2013) P O P C T

    WO 2013/061161 A2 2 May 2013 (02.05.2013) P O P C T

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/061161 A2 2 May 2013 (02.05.2013) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/337 (2006.01) A61K 31/48 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/395 (2006.01) A61K 31/51 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/4174 (2006.01) A61K 31/549 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A61K 31/428 (2006.01) A61K 31/663 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (21) International Application Number: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, PCT/IB20 12/002768 ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (22) International Filing Date: NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, 25 October 2012 (25.10.2012) RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, (25) Filing Language: English ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 61/552,922 28 October 201 1 (28.
  • (12) United States Patent (10) Patent No.: US 8,039,019 B2 Hahn (45) Date of Patent: Oct

    (12) United States Patent (10) Patent No.: US 8,039,019 B2 Hahn (45) Date of Patent: Oct

    USO08039019B2 (12) United States Patent (10) Patent No.: US 8,039,019 B2 Hahn (45) Date of Patent: Oct. 18, 2011 (54) PHARMACEUTICAL FORMULATION (56) References Cited CONTAINING A BIGUANDE AND AN ANGOTENSIN ANTAGONST U.S. PATENT DOCUMENTS 5,196,444 A 3, 1993 Naka et al. (75) Inventor: Elliot F. Hahn, North Miami Beach, FL 5,534,534 A 7/1996 Makino et al. (US) 5,650,170 A 7/1997 Wright et al. 5,705,517 A 1/1998 Naka et al. (73) Assignee: Andrx Labs, LLC, Davie, FL (US) 6,099,859 A 8/2000 Cheng et al. 6,099,862 A 8, 2000 Chen et al. 6,682,759 B2 1/2004 Lim et al. (*) Notice: Subject to any disclaimer, the term of this 7,588,779 B2 9, 2009 Hahn patent is extended or adjusted under 35 2001 OO24659 A1 9, 2001 Chen et al. U.S.C. 154(b) by 54 days. 2004.0034.065 A1 2/2004 Allison et al. 2004/0106660 A1 6/2004 Kositprapa et al. (21) Appl. No.: 12/535,833 2004O161462 A1 8/2004 Kositprapa et al. 2004/0219209 A1 11/2004 Chen et al. (22) Filed: Aug. 5, 2009 2005/0226928 A1 10, 2005 LOdin et al. FOREIGN PATENT DOCUMENTS Prior Publication Data (65) WO WO9947 125 9, 1999 US 2009/O2976OO A1 Dec. 3, 2009 WO WOO215933 2, 2002 Related U.S. Application Data OTHER PUBLICATIONS Graffeo, M., International Search Report, PCT/US05/18939, Mar. 9. (62) Division of application No. 1 1/628,066, filed as 2006.
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances

    The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances

    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set

    Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set

    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
  • Pharmaceutical Appendix to the Tariff Schedule 2

    Pharmaceutical Appendix to the Tariff Schedule 2

    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9